SABS 2.56 (-7.58%)
US78397T1034BiotechnologyBiotechnology

SAB Biotherapeutics (SABS) Stock Highlights

2.56 | -7.58%
2024-09-19 06:52:45
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company advancing a class of immunotherapies based on its human polyclonal antibodies. It develops fully human antibodies produced from transchromosomic (Tc) bovine herds targeted at addressing specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer.

Statistics

Range Today
2.56 2.93
Volume Today 16.5K
Range 1 Year
0.41 9
Volume 1 Year 6.35M
Range 3 Year
0.37 12.9
Volume 3 Year 169.85M
Range 10 Year
0.37 12.9
Volume 10 Year 175.98M

Highlights

Market Capitalization 25.75M (micro)
Floating Shares 5.99M
Current Price 2.56
Price To Earnings -0.45
Price To Revenue -2.33
Price To Book 0.56
Earnings Per Share -6.16
Payout Ratio 0%

Performance

Latest -7.58%
1 Month -1.92%
3 Months -19.5%
6 Months -53.45%
1 Year +349.12%
3 Years -74.45%
5 Years -74.95%
10 Years -74.95%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.